Pay in 4 interest-free payments of $470.00 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways
oxidative stress and pro-inflammatory cytokine production
The highest concentration
CAS Number: 75330-75-5
Bone morphogenetic protein-focused strategies to induce cytotoxicity in lung cancer cells
Trabectedin - CAS# 114899-77-3 pone A small-molecule inhibitor of UBE2NTrabectedin (also known as ecteinascidin 743 or ET 743, trade name Yondelis) is an antitumor chemotherapy drug sold by Pharma Mar S. A. and Johnson and Johnson under the brand name Yondelis. It is approved for use in Europe, Russia, and South Korea for the treatment of advanced soft tissue sarcoma. It is also undergoing clinical trials for the treatment of breast, prostate, and paediatric sarcomas. The European Commission and the U. S. Food and Drug